New evidence links flavan-3-ols and mortality in the MetS population
Clinical context: polyphenols and risk in metabolic syndrome
Metabolic syndrome (MetS)—a combination of abdominal obesity, hypertension, dyslipidemia, and insulin resistance—affects a significant proportion of the adult population and is associated with increased mortality.
In this scenario, dietary bioactive compounds, particularly flavan-3-ols (catechins found in tea, cocoa, fruit, and red wine), are of growing interest for their antioxidant and anti-inflammatory potential.
The study analyzed explores whether higher dietary intake of flavan-3-ols is associated with reduced mortality risk in the MetS population.
Study design
The authors used three NHANES cycles (2007–2008, 2009–2010, 2017–2018), linking dietary data to mortality records from the National Death Index up to December 31, 2019.
Flavan-3-ols intake and individual monomers (catechin, epicatechin, epigallocatechin, gallocatechin, and gallate forms) were estimated by cross-referencing 24-h dietary recalls with the USDA Flavonoid and FNDDS databases. After rigorous exclusion criteria, the final sample included 2,185 adults with MetS, representative (with sample weights) of about 27 million U.S. adults.
To estimate associations between intake and mortality, the researchers used Cox models with multiple levels of adjustment, Kaplan–Meier curves, and restricted cubic splines to assess potential non-linear trends. Subgroup analyses (age, sex, BMI, income, comorbidities) and interaction tests were also conducted.
Main results: lower total mortality with higher flavan-3-ols
Over a median follow-up of 114 months, 329 deaths occurred. In the fully adjusted model, those in the highest tertile of flavan-3-ols intake had a 33% lower risk of all-cause mortality compared with the lowest tertile (HR = 0.67; 95% CI: 0.49–0.92; p for trend = 0.01).
Looking at the monomers, the protective association was consistent:
- Epigallocatechin (EGC): HR ≈ 0.55 for the highest vs lowest levels.
- Catechin (C): HR ≈ 0.57 in the highest tertile.
- Epicatechin gallate (ECG), epigallocatechin gallate (EGCG), and gallocatechin (GC): HR between 0.66 and 0.71 when present in the diet compared to zero values.
Kaplan–Meier curves showed survival differences in favor of groups with higher intake. Importantly, no significant associations with cardiovascular mortality emerged after full adjustment.
Dose–response and subgroups: no non-linearity, consistent signals
Restricted cubic splines did not suggest a non-linear relationship: the protective effect appears to progress linearly with increasing dietary intake. In subgroups, the benefit was particularly evident in subjects >60 years, in women, and at lower income levels; however, interaction tests were not significant, suggesting that the effect does not differ substantially across these characteristics.
Interpretation: a robust but observational signal
Overall, the study indicates that a diet rich in flavan-3-ols is associated with lower all-cause mortality in people with metabolic syndrome. The absence of a link with cardiovascular mortality may reflect statistical power limits (few events) or suggest that benefits extend beyond cardiovascular outcomes (e.g., infections, cancers, respiratory causes). In any case, as an observational study, causal inference is not possible.
Biological mechanisms: antioxidants, anti-inflammatory action, and endothelial function
Flavan-3-ols may modulate oxidative stress and inflammation, two central drivers of MetS. Catechins:
- neutralize reactive oxygen species and chelate pro-oxidant metals;
- activate antioxidant pathways (Nrf2) and increase scavenger enzymes (SOD, CAT, GSH-Px);
- reduce pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and NF-κB activation;
- may enhance endothelial function and nitric oxide bioavailability.
These mechanisms are consistent with the hypothesis of lower risk of adverse outcomes in metabolically compromised individuals.
Dietary sources and safety: diet yes, supplements with caution
Main dietary sources include tea (especially green), cocoa and dark chocolate, fruits (e.g., apples, berries), and red wine in moderate consumption. The study highlights a crucial point for practice: benefits emerge in the context of overall diet, not from concentrated extracts.
Excess catechin supplements (e.g., high-dose EGCG) have been associated with hepatic and gastrointestinal adverse events under certain conditions. The most recent nutritional guidelines on flavan-3-ols suggest daily intake ranges (e.g., 400–600 mg/day) realistically achievable through foods, avoiding risks linked to high-dose extracts.
One more piece toward personalized prevention
This large cohort study suggests that in people with metabolic syndrome, higher dietary flavan-3-ols consumption is associated with lower all-cause mortality. Despite the limitations of observational studies, the signal aligns with polyphenol biology and previous prospective evidence.
For everyday practice, the message is pragmatic: strengthening dietary sources of flavan-3-ols within an overall healthy eating pattern can represent a simple, sustainable, and potentially impactful measure.
if your company is interested in creating or manufacturing a product for metabolic syndrome:
Source: 2025, “Relationship between dietary flavan-3-ols intake and mortality in metabolic syndrome population; a large cohort study”, Frontiers in Nutrition.
